Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-escalation protocol for capecitabine and achievable dose in the 4th chemotherapy cycle
TCTR20230407003Phase 2Terminated
- Sponsor
- principal investigator
- Start
- Jul 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of capecitabine, sponsored by principal investigator. Started Jul 2021; status: terminated.
02
Drugs
capecitabine
Beyond the preview
Go deeper on TCTR20230407003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230407003.